TY - JOUR
T1 - New agents in acute myeloid leukemia
T2 - Beyond cytarabine and anthracyclines
AU - Fathi, Amir T.
AU - Karp, Judith E.
PY - 2009
Y1 - 2009
N2 - The standard therapeutic approaches for acute myeloid leukemia (AML) continue to be based on anthracyclines and cytarabine. However, the prognosis for AML remains poor, especially for patients with high-risk disease. During the past decade, promising novel agents that target DNA replication and repair, as well as cell cycling and apoptosis, have been developed and are being actively investigated in AML. Among these agents is flavopiridol, which interferes with key steps of the cell cycle and effectively promotes cell death, and voreloxin, an intercalating agent that also targets topoisomerase II. Also under clinical study in AML are oligonucleotide antisense constructs, which suppress the translation of proteins essential for leukemic blast survival and proliferation, and agents that target antiapoptotic cascades. In summary, it is hoped that novel therapies such as these will augment and/or supplant our current cytarabine- and anthracycline-based approaches, overcome active drug-resistance pathways, and eventually improve outcomes for patients with AML.
AB - The standard therapeutic approaches for acute myeloid leukemia (AML) continue to be based on anthracyclines and cytarabine. However, the prognosis for AML remains poor, especially for patients with high-risk disease. During the past decade, promising novel agents that target DNA replication and repair, as well as cell cycling and apoptosis, have been developed and are being actively investigated in AML. Among these agents is flavopiridol, which interferes with key steps of the cell cycle and effectively promotes cell death, and voreloxin, an intercalating agent that also targets topoisomerase II. Also under clinical study in AML are oligonucleotide antisense constructs, which suppress the translation of proteins essential for leukemic blast survival and proliferation, and agents that target antiapoptotic cascades. In summary, it is hoped that novel therapies such as these will augment and/or supplant our current cytarabine- and anthracycline-based approaches, overcome active drug-resistance pathways, and eventually improve outcomes for patients with AML.
UR - http://www.scopus.com/inward/record.url?scp=68949163145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68949163145&partnerID=8YFLogxK
U2 - 10.1007/s11912-009-0047-x
DO - 10.1007/s11912-009-0047-x
M3 - Review article
C2 - 19679009
AN - SCOPUS:68949163145
SN - 1523-3790
VL - 11
SP - 346
EP - 352
JO - Current oncology reports
JF - Current oncology reports
IS - 5
ER -